Figures & data
Figure 1 Experimental design. Five groups of mice (n=8 per group) were used in the experiment.
Abbreviations: AHR, airway hyperresponsiveness; PLGA, poly(lactic-co-glycolic acid); rCmP, recombinant Caryota mitis profilin; SIT, specific immunotherapy; ip, intraperitoneal injection; sc, subcutaneous injection; in, nasal inhalation.
Figure 2 (A) Field emission scanning electron microscopic image, (B) dynamic light scattering spectra, and (C) in vitro cumulative protein release of rCmP-loaded PLGA nanoparticles.
Abbreviations: PLGA, poly(lactic-co-glycolic acid); rCmP, recombinant Caryota mitis profilin; NPs, nanoparticles.
Figure 3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis of rCmP-loaded PLGA nanoparticles.
Notes: M, marker; 1, PLGA-rCmP; 2, rCmP.
Abbreviations: PLGA, poly(lactic-co-glycolic acid); rCmP, recombinant Caryota mitis profilin.
Figure 4 Western blot of rCmP-loaded PLGA nanoparticles with serum from patient.
Notes: M, marker; 1, PLGA-rCmP; 2, rCmP.
Abbreviations: PLGA, poly(lactic-co-glycolic acid); rCmP, recombinant Caryota mitis profilin.
Figure 5 Airways hyperresponsiveness assay for mice.
Notes: Normal, healthy control group; model, untreated asthma model group; PLGA-rCmP, rCmP-loaded PLGA nanoparticle group; PLGA, blank PLGA nanoparticle control group; and rCmP, rCmP/Al(OH)3 vaccine group.
Abbreviations: PLGA, poly(lactic-co-glycolic acid); rCmP, recombinant Caryota mitis profilin.
Figure 6 Allergen-specific antibodies in serum.
Notes: A450, absorbance at 450 nm; normal, healthy control group; model, untreated asthma model group; PLGA-rCmP, rCmP-loaded PLGA nanoparticle group; PLGA, blank PLGA nanoparticle control group; rCmP, rCmP/Al(OH)3 vaccine group. *P<0.05, **P<0.01 versus untreated asthma model control group.
Abbreviations: PLGA, poly(lactic-co-glycolic acid); rCmP, recombinant Caryota mitis profilin; OD, optical density.
Figure 7 Differential counts of inflammatory cells in BALF.
Notes: Normal, healthy control group; model, untreated asthma model group; PLGA-rCmP, rCmP-loaded PLGA nanoparticle group; PLG, blank PLGA nanoparticle control group; rCmP, rCmP/Al(OH)3 vaccine group. *P<0.05, **P<0.01 versus untreated asthma model control group.
Abbreviations: BALF, bronchoalveolar lavage fluid; PLGA, poly(lactic-co-glycolic acid); rCmP, recombinant Caryota mitis profilin.
Figure 8 Cytokine production in spleen cell cultures (A) and BALF (B).
Notes: Normal, healthy control group; model, untreated asthma model group; PLGA-rCmP, rCmP-loaded PLGA nanoparticle group; PLGA, blank PLGA nanoparticle control group; rCmP, rCmP/Al(OH)3 vaccine group. *P<0.05, **P<0.01 versus untreated asthma model control group.
Abbreviations: BALF, bronchoalveolar lavage fluid; PLGA, poly(lactic-co-glycolic acid); rCmP, recombinant Caryota mitis profilin; IL-4, interleukin-4; IL-10, interleukin-10; IFN-γ, interferon-gamma.
Figure 9 Formalin-fixed lung sections were stained with hematoxylin and eosin.
Notes: Normal, healthy control group; model, untreated asthma model group; PLGA-rCmP, rCmP-loaded PLGA nanoparticle group; PLGA, blank PLGA nanoparticle control group; rCmP, rCmP/Al(OH)3 vaccine group.
Abbreviations: PLGA, poly(lactic-co-glycolic acid); rCmP, recombinant Caryota mitis profilin.
